Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1991-5-21
|
| pubmed:abstractText |
Pentoxifylline (Trental), used routinely for the treatment of intermittent claudication, has been shown previously to decrease the levels of tumor necrosis factors-alpha (TNF-alpha) RNA in cancer patients and to lead to a general improvement of well being. Increased TNF-alpha levels have been observed not only in cancer patients but also in cachectic patients with the acquired immunodeficiency syndrome (AIDS), and TNF-alpha is known to increase the expression of the human immunodeficiency virus type 1 (HIV-1) via activating its long terminal repeat (LTR). Moreover, TNF-alpha decreases the therapeutic efficacy of zidovudine (AZT). Here we show a significant decrease in HIV-1 replication by pentoxifylline in infected human peripheral blood mononuclear cells. The reduction was proportional to the downregulation of expression of a reporter gene, the bacterial gene for chloramphenicol acetyl transferase, linked to the HIV-1 LTR in human monocytoid cells. We conclude that patients with AIDS may benefit from pentoxifylline treatment because of its blockage of TNF-alpha-mediated HIV-1 upregulation, from increased efficacy of AZT, and also from improvement in TNF-alpha-induced cachexia.
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Actins,
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotide Probes,
http://linkedlifedata.com/resource/pubmed/chemical/Pentoxifylline,
http://linkedlifedata.com/resource/pubmed/chemical/RNA,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
77
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1653-6
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:1707692-Actins,
pubmed-meshheading:1707692-Antiviral Agents,
pubmed-meshheading:1707692-Base Sequence,
pubmed-meshheading:1707692-Cell Line,
pubmed-meshheading:1707692-Cells, Cultured,
pubmed-meshheading:1707692-Gene Expression Regulation, Viral,
pubmed-meshheading:1707692-HIV Long Terminal Repeat,
pubmed-meshheading:1707692-HIV-1,
pubmed-meshheading:1707692-Humans,
pubmed-meshheading:1707692-Kinetics,
pubmed-meshheading:1707692-Leukocytes, Mononuclear,
pubmed-meshheading:1707692-Molecular Sequence Data,
pubmed-meshheading:1707692-Oligonucleotide Probes,
pubmed-meshheading:1707692-Pentoxifylline,
pubmed-meshheading:1707692-Polymerase Chain Reaction,
pubmed-meshheading:1707692-RNA,
pubmed-meshheading:1707692-T-Lymphocytes,
pubmed-meshheading:1707692-Tumor Necrosis Factor-alpha,
pubmed-meshheading:1707692-Virus Replication
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells.
|
| pubmed:affiliation |
Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Beth Israel Hospital, Boston, MA 02115.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|